Risultati preclinici e clinici con Gefitinib (ZD1839, Iressa) inibitore del recettore per il fattore di crescita epidermoidale

Translated title of the contribution: Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)

S. Di Cosimo, G. Ferretti, M. Milella, E. Martinelli, A. Alimonti, P. Papaldo, P. Carlini, A. Fabi, P. Matar, F. Cognetti

Research output: Contribution to journalArticle

Abstract

Since epidermal growth factor receptor (EGFR) is involved in tumor proliferation and angiogenesis, and in the mechanisms of resistance to chemo- and hormono-therapy, it represents a unique promising target for anticancer treatment. Gefinitib (Iressa, ZD1839), an inhibitor of the EGFR tyrosine kinase activity able to bind the intracellular domain of the receptor, is at present in clinical development. In preclinical models Gefitinib induced a dose-dependent response rate in tumor xenografts obtained from different human cancer cells lines. The expression of EGFR in the prior tumor did not appear to be a predictive marker for Gefitinib sensitivity. Furthermore, long-term drug use was well tolerated in mice without inducing resistance. However, tumors started to grow again after treatment interruption. Laboratory findings and in vivo data have prompted the evaluation of Gefitinib administered as a single oral daily dose alone or in combination with conventional anticancer treatment.

Translated title of the contributionPreclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)
Original languageItalian
Pages (from-to)233-241
Number of pages9
JournalMinerva Medica
Volume95
Issue number3
Publication statusPublished - Jun 2004

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)'. Together they form a unique fingerprint.

  • Cite this